Pancreatic Cancer
Pancreatic cancer cells react to structurally optimized celecoxib derivative
Published in Cancer Weekly, April 10th, 2006
According to a study from the United States, "Deregulation of the phosphatidylinositol 3-kinase (PI-3K)/PDK-1/Akt signaling cascade is associated with pancreatic cancer tumor invasion, angiogenesis, and tumor progression. As such, it has been postulated that PDK-1/Akt signaling inhibitors may hold promise as novel therapeutic agents for pancreatic cancer."
"Disadvantages of currently available Akt inhibitors include tumor resistance, poor specificity, potential toxicity, and poor bioavailability. Previous studies have demonstrated that OSU-03012, a celecoxib derivative,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-04-10)
More Articles from Cancer Weekly
- Lung Cancer
Quinuclidinone analogs examined as anti-proliferative agents in lung cancer - Pheochromocytomas
Pheochromocytoma linked to clusterin expression - Prostate Cancer
Prostate cancer linked to 90K/Mac-2 binding protein expression - Rhabdomyosarcomas
Mel-resistant rhabdomyosarcoma cells sensitized to melphalan by TRAIL - Acute Myeloid Leukemia
Acute myeloid leukemia outcome not improved after daunorubicin, cytarabine, and thioguanine therapy - Antisense Technology
Antisense oligonucleotide library validates Eg5 as a drug development target - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
